Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy

Executive Summary

Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.

Advertisement

Related Content

Bangladesh HCV Market: Can Generic Epclusa Shake Things Up?
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
Natco CEO On Dynamics In The HCV Market
Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing
EASL 2016: Looking For A Competitive Edge In Hepatitis C

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register